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Investigation of the human antibody response to influenza virus infection has been largely limited to serology, with relatively little analysis at the molecular level. The 1918 H1N1 influenza virus pandemic was the most severe of the modern era 1 . Recent work has recovered the gene sequences of this unusual strain 2 , so that the 1918 pandemic virus could be reconstituted to display its unique virulence phenotypes 3, 4 . However, little is known about adaptive immunity to this virus. We took advantage of the 1918 virus sequencing and the resultant production of recombinant 1918 haemagglutinin (HA) protein antigen to characterize at the clonal level neutralizing antibodies induced by natural exposure of survivors to the 1918 pandemic virus. Here we show that of the 32 individuals tested that were born in or before 1915, each showed seroreactivity with the 1918 virus, nearly 90 years after the pandemic. Seven of the eight donor samples tested had circulating B cells that secreted antibodies that bound the 1918 HA. We isolated B cells from subjects and generated five monoclonal antibodies that showed potent neutralizing activity against 1918 virus from three separate donors. These antibodies also cross-reacted with the genetically similar HA of a 1930 swine H1N1 influenza strain, but did not cross-react with HAs of more contemporary human influenza viruses. The antibody genes had an unusually high degree of somatic mutation. The antibodies bound to the 1918 HA protein with high affinity, had exceptional virus-neutralizing potency and protected mice from lethal infection. Isolation of viruses that escaped inhibition suggested that the antibodies recognize classical antigenic sites on the HA surface. Thus, these studies demonstrate that survivors of the 1918 influenza pandemic possess highly functional, virus-neutralizing antibodies to this uniquely virulent virus, and that humans can sustain circulating B memory cells to viruses for many decades after exposure-well into the tenth decade of life.
Recent studies suggest that the 1918 H1N1 influenza virus was of avian origin 2, 5 , and is capable of inducing strong systemic cytokine responses that probably contribute to pathogenesis 4, 6 . Little is known about naturally occurring adaptive immunity to this virus; however, some elderly survivors are still living. We sought to determine whether survivors showed evidence of acquired immunity to the virus. Expression of the 1918 HA antigen allowed us to identify and characterize protective antibodies induced by natural exposure of humans to the 1918 pandemic virus.
We identified a panel of 32 subjects aged 91-101 years (that is, aged from 2 to 12 in 1918), many of whom recalled a sick family member in the household during the pandemic, which suggested direct exposure to the virus. Of the subjects tested, 100% had serum-neutralizing activity against the 1918 virus (mean titre 1:562), and 94% had serologic reactivity to the 1918 HA (as indicated by haemagglutination inhibition assay (HAI) titres of 1:40 or greater; mean titre 1:396), even though these samples were obtained nearly 90 years after the pandemic. In contrast, subjects born after the pandemic had markedly lower rates of positive serum-neutralizing tests against the 1918 virus (9 out of 10 subjects born 1926-35 had titres ,1:100, 9 out of 10 subjects born 1936-45 had titres #1:40, 9 out of 10 subjects born 1946-55 had titres #1:40). Individual serologic results are shown in Supplementary Table 1 .
Peripheral blood mononuclear cells from eight subjects were isolated and B lymphoblastic cell lines were generated by transformation; blood from almost all of the donors tested We collected transformed cells from the wells corresponding to supernates showing the highest levels of specific binding to the 1918 HA (derived from five donors) and fused them to the HMMA2.5 nonsecreting myeloma partner 7 using an electrofusion technique 8 . We isolated 17 unique hybridoma cell lines that secreted antibodies reactive with the 1918 HA from cell lines derived from four out of five donors, and then segregated the lines by limiting dilution to yield monoclonal antibody secreting clones. Our screening identified five independent lines with HAI activity against 1918 virus from three separate donors, which we biologically cloned and designated monoclonal antibodies 1I20, 1F1 and 2B12 (donor 6), monoclonal antibody 4D20 (donor 4) and monoclonal antibody 2D1 (donor 23).
Sequence analysis of the antibody genes from the clones demonstrated that the five monoclonal antibodies were distinct and very highly mutated. Genetic features of the antibodies are shown in Table 1 . It was of interest that the 1F1, 2B12 and 2D1 clones shared use of the VL1-44*01 gene segment, suggesting a particular fitness for binding of the 1918 virus HA by the CDR1/2 light-chain loops encoded by this VL gene segment. The three clones, however, were clearly independent as they differed in the location of somatic mutations, JL segment (1F1) and in heavy-chain pairing. The numbers of somatic mutations in the variable regions were exceptionally large, almost twice the median number of 18 mutations found in class-switched memory cells in randomly selected human B cells 9 . These data probably suggest recurrent optimization of binding affinity through multiple rounds of somatic hypermutation and selection in vivo.
Purified monoclonal antibodies were assessed by ELISA against a series of representative twentieth century H1N1 viruses including human isolates from 1918, 1943, 1947, 1977 and 1999 . We also examined reactivity with influenza A/Swine/Iowa/15/30 (H1N1) virus, as the HA sequence of this virus more closely resembles the 1918 HA sequence than the sequence of any other existing isolate does. The monoclonal antibodies bound to the 1918 HA, with clear cross-reactivity with the 1930 strain, suggesting the remote origin of the antibodies ( Fig. 1 and Supplementary Fig. 1 ). The 1F1 clone also bound to a minimal degree to the 1977 strain, a virus that is almost identical to isolates from the early 1950s 10 , and minimally to a 1943 isolate, but not to other post-1930 strains. The antibodies also bound to the corresponding HA expressed on the surface of mammalian cells following transfection of a complementary DNA encoding the 1918 HA as detected by immunofluorescence microscopy ( Supplementary Fig. 2 ). The antibodies did not bind to influenza H3, B or H5 HA proteins in ELISA (data not shown). All five antibodies proved to have very high affinities for recombinant 1918 HA protein when tested by surface plasmon resonance, ranging from 5.4 3 10 29 to 4.8 3 10 211 M (Table 1) . We tested five purified monoclonal antibodies from three separate donors for inhibitory activity in an HAI assay using 1918 virus-like particles (VLP) or a panel of H1N1 viruses. The antibodies showed specific binding for 'old' viruses, including the 1918 virus or viruses that were genetically similar to the 1918 virus (Table 2 and  Supplementary Table 2 Fig. 3 ), using the previous numbering scheme 11 . Escape mutants for 1F1 and 1I20 possessed an identical mutation, P186H, at a residue adjacent to the previously Fig. 3) , which encompasses the a-helix of the receptor binding site in the 1918 HA structure [11] [12] [13] . As expected, incorporation of the Sb antigenic site mutation into VLP reduced (1I20) or eliminated (1F1) activity of the corresponding antibodies in an HAI assay without affecting binding of 2B12 ( Table 2 ). The 2D1 and 4D20 antibodies also had reduced HAI activity against the site Sb mutant viruses and VLP, suggesting that they also bound to this site. In contrast, incorporation of the Sa mutation into VLP abolished activity of 2B12 in the HAI assay, but did not affect the activity of the other four antibodies ( Table 2 ). The 1918 and Sw/30 virus HAs differ by only a single amino acid in each of the Sa and Sb sites ( Supplementary Fig. 3 ), explaining why these antibodies cross-neutralize both viruses. In contrast, the 1943 isolate contains seven changes in the Sa site and seven changes in the Sb site, relative to the 1918 HA sequence, explaining the partial or complete loss of neutralizing ability of the antibodies for these later isolates. Notably, 9 of the 12 residues at the Sb site differed between the 1918 and the 1977 virus. The ability of 1F1 to cross-neutralize the 1977 virus despite its divergence from the 1918 virus is worthy of further investigation, because these data raise the possibility that 1F1 recognizes a new, more broadly neutralizing epitope. Alternatively, the data may represent epitope recycling such that, despite significant sequence divergence, the 1F1 epitope reappeared. In either case, further characterization of this antibody may suggest strategies to elicit enhanced cross-protective immunity to influenza A viruses of a particular HA subtype.
We tested the five antibodies for therapeutic efficacy in an established mouse model of infection. Mice were inoculated by the intranasal route with the previously reconstructed 1918 virus, and morbidity (measured by weight loss), mortality and virus replication were assessed as previously described 3 . Each of the five 1918-specific monoclonal antibodies tested showed therapeutic efficacy when administered 1 day after infection, preventing death of animals ( Table 2 ). Mice treated with a control (H5 HA-specific) human monoclonal antibody or human IgG did not survive. Reduced weight loss and lower levels of virus replication in the lungs of anti-1918-antibody-treated mice on day 4 after infection also demonstrated a significant protective effect that correlated well with survival data. At lower doses, the antibodies caused a statistically significant delay to death, relative to the controls.
These studies suggest that B cells responding to viral infections, or their progeny, survive for the life of the host, even nine or more decades after exposure. It is well established that a subset of plasma cells is long-lived 14 , and these cells contribute to durable humoral immune responses 15 , such as that observed after childhood smallpox vaccination [16] [17] [18] [19] . Memory B cell pools also can be long-lived, sustained in part by antigen-independent polyclonal stimuli 20 . It is difficult to be absolutely certain that the monoclonal antibodies isolated here were first stimulated by exposure during the 1918 pandemic. However, the clinical history of the subjects and the high functional specificity of the monoclonal antibodies for the 1918 strain strongly suggest that recent exposures do not account for this immunity. Probably, boosting by antigenically related viruses in the early decades of the twentieth century may have contributed to the ability of these subjects to sustain these B cells. The variable genes of five independent human neutralizing antibodies had a very high frequency of somatic mutations, associated with strong binding constants and high potency. The in vivo efficacy of treatment with these antibodies shows that the development of functional adaptive immunity to the pandemic virus did occur in survivors of the 1918 pandemic.
It has long been known that infusion of neutralizing antibodies can protect mice from lethal influenza virus infection, and transfusion of convalescent blood products to 1918 influenza victims may have had a beneficial effect 21 . Thus, the monoclonal antibodies described here could serve as potential therapeutics for a re-emergent 1918-like virus. The techniques described here suggest that it may be possible to recover human antibodies that display a wide array of specificities corresponding to the viruses and other pathogens that have infected an individual during their lifetime.
METHODS SUMMARY
Recombinant 1918 virus HA (A/South Carolina/1/1918) was produced as described 11 . Peripheral blood mononuclear cells were obtained from volunteers born in 1915 or earlier. Hybridomas were generated from EBV-transformed B cell lines by electrofusion to the HMMA2.5 cell line 7, 8 . When hybridoma lines formed colonies in the presence of selecting drugs, lines were cloned by limiting dilution. Secreted monoclonal antibodies were concentrated and purified by fast protein liquid chromatography (FPLC). The isotype and subclass of secreted antibodies were determined by ELISA. Nucleotide sequences of variable gene segments were determined by automated sequence analysis of cloned cDNA 22 . The identity of the gene segments and mutations from the germline sequences were determined by alignment using the ImMunoGeneTics database 23 . Viruses were propagated in 10-day-old embryonated chicken eggs. Influenza A/South Carolina/1/18 virus was prepared as previously described 3 . Expression plasmids encoding the 1918 HA and neuraminidase (NA) proteins were described previously 24, 25 . Binding of antibodies was determined using 1918 VLP or influenza A viruses as the coating antigen in ELISA. VLP were produced by co-transfection of 293T cells with expression plasmids for the 1918 HA and 1918 NA, consistent with a recent report 26 . HAI assays of sera or antibodies were performed according to standard protocols using chicken red blood cells 27 . For microneutralization assay, ten 50% tissue-culture infective dose units (TCID 50 ) of virus was preincubated with dilutions of sera or monoclonal antibody and then used to infect Madin-Darby canine kidney (MDCK) cells in 96-well plates, as described 28, 29 . The kinetic interaction of monoclonal antibodies with the 1918 HA protein was determined by surface plasmon resonance. Antibody escape mutants were isolated by treatment of Sw/30 virus with excess antibody as described 12, 30 . Mice were inoculated intranasally with five LD 50 (lethal dose to 50% of animals) of the 1918 virus. At 24 h after inoculation, we administered 1918-specific monoclonal antibody or control antibodies to each mouse. Mice were observed for weight loss or death. Subsets of animals were killed for virus titre.
Full Methods and any associated references are available in the online version of the paper at www.nature.com/nature.
In this Letter, the heavy-chain sequence of 1F1 was in error and has been corrected in GenBank (EU169674.2). Also, the 1947 virus tested that was not inhibited by 1F1 should have been designated A/USA/ L3/1947(H1N1) rather than A/Fort Monmouth/1/1947(H1N1). In addition, 1F1 exhibits HAI activity of 1.3 mg ml 21 (not undetectable) against A/Fort Monmouth/1/1947 virus. These errors do not affect our main conclusions. These errors have been corrected in the HTML and PDF of the original paper (particularly Table 1 and Fig. 1 ) and in the original Supplementary Information.
